Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension

Cardiovascular Research

Volumn 115, Issue 2, 2019, Pages 432-439

  Rol, Nina ^a,b   De Raaf, Michiel A ^a,b   Sun, Xiaoqing Q ^a   Kuiper, Vincent P ^a   Da Silva Gonçalves Bos, Denielli ^a,b   Happé, Chris ^a,b   Kurakula, Kondababu ^c   Dickhoff, Chris ^a   Thuillet, Raphael ^d,e   Tu, Ly ^d,e   Guignabert, Christophe ^d,e   Schalij, Ingrid ^a,b   Lodder, Kirsten ^c   Pan, Xiaoke ^a,b   Herrmann, Franziska E ^f   Van Nieuw Amerongen, Geerten P ^b   Koolwijk, Pieter ^b   Vonk Noordegraaf, Anton ^a   De Man, Frances S ^a,b   Wollin, Lutz ^f   Goumans, Marie José ^c   Szulcek, Robert ^a,b   Bogaard, Harm J ^a   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Universite Paris Sud   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Boehringer Ingelheim Pharma GmbH and Co Biberach   (Germany)

Author keywords

Cardiac fibrosis; Endothelial cell; Pulmonary arterial hypertension; Tyrosine kinase inhibitor; Vascular remodelling

Indexed keywords

COLLAGEN TYPE 3; NINTEDANIB; RNA; SEMAXANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; EXPERIMENTAL PULMONARY HYPERTENSION; EXTRACELLULAR MATRIX; HEART CATHETERIZATION; HEART FIBROBLAST; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; LUNG RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY VASCULAR DISEASE; RAT; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE; TISSUE SECTION; ADULT; ANIMAL; CARDIAC MUSCLE; CELL CULTURE; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; FIBROSIS; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; VASCULAR REMODELING; YOUNG ADULT;

ADULT; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; INDOLES; MALE; MYOCARDIUM; PROTEIN KINASE INHIBITORS; PULMONARY ARTERIAL HYPERTENSION; PULMONARY ARTERY; PYRROLES; RATS, SPRAGUE-DAWLEY; VASCULAR REMODELING; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 85060365403     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvy186     Document Type: Article

References (42)

1. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.
2. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012; 40: 1555-1565.
3. Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y, Humbert M, Montani D. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a doubleedge sword? Semin Respir Crit Care Med 2013; 34: 714-724.
4. Guignabert C, Tu L, Girerd B, Ricard N, Huertas A, Montani D, Humbert M. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 2015; 147: 529-537.
5. Gomez-Arroyo J, Sakagami M, Syed AA, Farkas L, Van TB, Kraskauskas D, Mizuno S, Abbate A, Bogaard HJ, Byron PR, Voelkel NF. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J 2015; 45: 449-462.
6. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jais X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
7. Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, Chaumais MC, Bouchet S, Maneglier B, Molimard M, Rousselot P, Sitbon O, Simonneau G, Montani D, Humbert M. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest 2016; 126: 3207-3218.
8. Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, Bouvaist H, Magro P, Bergeron A, Guignabert C, Sitbon O, Simonneau G, Humbert M, Montani D. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017; 50: 1700217.
9. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le PJ, Mazmanian M, Fadel E, Mussot S, Mercier O, Herve P, Emilie D, Eddahibi S, Simonneau G, Souza R, Humbert M. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
10. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009; 34: 662-668.
11. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
12. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
13. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
14. Benisty JI, McLaughlin VV, Landzberg MJ, Rich JD, Newburger JW, Rich S, Folkman J. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 2004; 126: 1255-1261.
15. Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, Humbert M, Eddahibi S, Guignabert C. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011; 45: 311-322.
16. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, Zadigue P, Dartevelle P, Simonneau G, Adnot S, Maitre B, Raffestin B, Eddahibi S. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009; 119: 512-523.
17. Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol 2014; 51: 474-484.
18. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209-L221.
19. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, Jonigk D, Maegel L, Bockmeyer CL, David S, Hoeper MM. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 2291-2300.
20. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434-1445.
21. Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid 2015; 10: 89-98.
22. Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and antiinflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014; 349: 209-220.
23. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
24. Richeldi L, Cottin V, Du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med 2016; 113: 74-79.
25. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al HA, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ 2012; 2: 434-442.
26. Szulcek R, Happe CM, Rol N, Fontijn RD, Dickhoff C, Hartemink KJ, Grunberg K, Tu L, Timens W, Nossent GD, Paul MA, Leyen TA, Horrevoets AJ, de Man FS, Guignabert C, Yu PB, Vonk-Noordegraaf A, van Nieuw Amerongen GP, Bogaard HJ. Delayed microvascular shear-adaptation in pulmonary arterial hypertension: role of PECAM-1 cleavage. Am J Respir Crit Care Med 2016; 193: 1410-1420.
27. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research. Circ Res 2018; 122: 1021-1032.
28. van der Heijden M, van Nieuw Amerongen GP, van BJ, Paul MA, Groeneveld AB, van Hinsbergh VW. Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. PLoS One 2011; 6: e23448.
29. de Raaf MA, Schalij I, Gomez-Arroyo J, Rol N, Happe C, de Man FS, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, Bogaard HJ. SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction. Eur Respir J 2014; 44: 160-168.
30. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 1997; 151: 1019-1025.
31. Meadows KN, Bryant P, Vincent PA, Pumiglia KM. Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 2004; 23: 192-200.
32. Bogaard HJ, Abe K, Vonk NA, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135: 794-804.
33. Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmuller P, Guignabert C, Humbert M, Macdonald P, Dos Remedios C, Postmus PE, Saripalli C, Hidalgo CG, Granzier HL, Vonk-Noordegraaf A, van der Velden J, de Man FS. Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation 2013; 128: 2016-2025, 1-10.
34. Awad KS, Elinoff JM, Wang S, Gairhe S, Ferreyra GA, Cai R, Sun J, Solomon MA, Danner RL. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2016; 310: L187-L201.
35. Abe K, Toba M, Alzoubi A, Koubsky K, Ito M, Ota H, Gairhe S, Gerthoffer WT, Fagan KA, McMurtry IF, Oka M. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 2011; 45: 804-808.
36. Pankey EA, Thammasiboon S, Lasker GF, Baber S, Lasky JA, Kadowitz PJ. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol 2013; 305: H1288-H1296.
37. Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock 2007; 28: 4-14.
38. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc MG, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-438.
39. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005; 19: 1178-1180.
40. Happe CM, de Raaf MA, Rol N, Schalij I, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, de Man FS, Bogaard HJ. Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol 2016; 310: L1088-L1097.
41. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, Ockaili R, McCord JM, Voelkel NF. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009; 120: 1951-1960.
42. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011; 183: 1402-1410.